AI assistant
Indivior PLC — Director's Dealing 2026
Feb 12, 2026
4923_dirs_2026-02-12_e78410ac-e778-45c6-b035-3935b10992ce.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Indivior Pharmaceuticals, Inc. (INDV)
CIK: 0001625297
Period of Report: 2026-02-09
Reporting Person: Anderson Woodrow D (Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-10 | Common Stock | A | 6903 | — | Acquired | 11293 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | Performance Stock Units | $0 | A | 23975 | Acquired | Common Stock (23975) | Direct |
Footnotes
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on
February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.
F2: On March 3, 2023, the Reporting Person was granted a conditional award for 23,975 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.